This Viewpoint discusses how the price negotiation for certain drugs under the Inflation Reduction Act will provide a unique opportunity to enhance access to therapies for older patients with cardiovascular conditions and diabetes.
No takes yet. Share an insight, caveat, or question.
Kazi et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: